Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

GRNOPC1 for spinal-cord injury

Drug (brand / generic)

GRNOPC1

Company / Licensee

Geron Corp.

Therapy Class

Stem cell therapy

Product Description

Human embryonic stem cell (hESC)-derived oligodendrocytes

Current Indication

Spinal cord injury

Market Sector

CNS

Current Status

Phase I
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top